CROSSJECT's strategic reorganization to support its expansion

CROSSJECT, a company specializing in emergency pharmaceutical solutions with its ZENEO® technology, is restructuring its governance to support its industrial and commercial expansion. The Executive Board is expanding with the addition of three new members: Olivier Lacombe, Didier Morin, and Lionel Seltz, joining Patrick Alexandre and Isabelle Liebschutz. This change addresses the need to coordinate the leaders of pharmaceutical development, industrialization, and financial and regulatory matters.

At the same time, CROSSJECT US is strengthening its team with the addition of David Pudwill, a regulatory affairs expert, to lead ZEPIZURE®'s US strategies. His appointment aims to reinforce relationships with the FDA and US strategic partners, thereby preparing for the industrialization and market distribution of ZENEO® platform products.